Clinical Study | Office of Clinical Research

Phase 3 Open-Label Extension Study Of Td-9855 For Treating Symptomatic Noh In Subjects With Primary Autonomic Failure (Oak)

Posted Date: Apr 30, 2021

Investigator: Alberto Espay
Specialties: Movement Disorders, Neurology, Parkinson's Disease
Type of Study: Drug

This is a Phase 3, multi-center, open-label study to evaluate the safety and tolerability of ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic nOH. The study consists of 3 periods: (i) 26-week treatment, (ii) 156-week treatment extension, and (iii) 2-week follow-up.

Criteria:

Inclusion Criteria: Completion Of Study 0170 And, In The Opinion Of The Investigator, Would Benefit From Long-Term Treatment With Ampreloxetine. The Subject Must Be Able To Understand The Nature Of The Study And Must Provide Written Informed Consent Prio

Keywords:

Orthostatic Hypotension, Neurology, Espay

For More Information:

Jessica (Doak) Marchbank
513-558-4811
jessica.doak@uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List